

Exclusive insights from MedImmune and Takeda at the 5th ADC Summit

LONDON, SELECT STATE/PROVINCE, UNITED KINGDOM, April 18, 2016 /EINPresswire.com/ -- With the pharmaceutical and biotech industry accelerating ADC development SMi Group's ADC Summit returns to London this Spring on 23rd and 24th May, followed by two post-conference workshops on 25th May.



Medimmune, who have entered a licensing agreement with Regeneron for usage of the former's PDB technology in aid of ADC cancer treatment, will be represented by R&D VP Dr Rakesh Dixit. Dr Dixit will open the conference with a keynote presentation addressing recent advancements in ADCs.



Medimmune, who have entered a licensing agreement with Regeneron for usage of the former's PDB technology in aid of ADC cancer treatment, will be represented by R&D VP Dr Rakesh Dixit.

SMi Group

Takeda, who have just agreed to collaborate with Mersana to commercialise the clinic-bound cancer therapy XMT-1522, will be participating in the conference through a presentation delivered by Dr Ashish Gautam, Global Medical Lead for ADCETRIS. Dr Gautam will be discussing how the FDA-approved ADC has been developed to treat Hodgkin Lymphoma.

King's College Professor David Thurston and Femtogenix Project Manager Paul Jackson will be hosting the first post-

conference workshop on ADC Payloads, focusing on the variety of chemical and biological payloads available for attaching to ADCs as well as those in the discovery and/or development phase.

Another exclusive post-conference workshop will explore developments in high potency API manufacturing and will be hosted by Richard Denk, Head of Sales Containment and Martin Glaettlim, Sales Engineering Containment at SKAN AG.

[Other event highlights include:](#)

- A presentation on predicting tissue distribution and clearance of antibody formats to improve selectivity of targeted therapies by Roche
- Analysis of the impact of drug loading on ADC target binding and cytotoxicity by Pfizer
- Challenges and lessons learnt in ADC CMC development and outsourcing by Novartis
- A case study on fragment drug conjugates (FDCs) from Antikor Biopharma
- Advances in novel site-specific conjugation tools by ImmunoGen
- Determining pre-clinical efficacy of a novel anti-C4.4a (LYPD3) ADC BAY 1129980 for the treatment of lung cancer with Bayer
- Learning how to produce better ADCs using ThioBridge conjugation with Abzena

- Development of best-in-class homogeneous ADCs for highly effective and safer cancer therapy with NBE-Therapeutics

The full speaker lineup can be viewed on the event website at <http://www.adcsummit.com>

The 5th ADC Summit is proudly sponsored by Abzena and Heraeus Pharma. For more information about tailored branding and sponsorship packages, please contact Alia Malick on +44(0)207 827 6184 or amalick@smi-online.co.uk.

5th ADC Summit
23 – 24 May 2016
Post-conference workshops: 25 May 2016
<http://www.adcsummit.com>

Honey de Gracia
SMi
2078276102
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.